Sunitinib induces macrophage dysfunction and impaired tissue regeneration through suppression of PPARγ
Frontiers in Immunology · 14.08.2026 · 17
DOI: 10.3389/fimmu.2026.1900449 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 14.08.2026. Verfasst von Zhouchen Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, China. Hauptthemen laut MEDLINE: Sunitinib, PPAR gamma, Macrophages, Regeneration. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Sunitinib is a widely used multi-target tyrosine kinase inhibitor associated with side effects that may impair tissue repair and regeneration, potentially contributing to the onset of medication-related osteonecrosis of the jaw. Macrophages play a central role in tissue homeostasis and regeneration, and their dysfunction may be a key factor in this pathological process.
Methods
In this study, a zebrafish tail fin injury regeneration model was used to investigate the effects of sunitinib on macrophage function and tissue regeneration. Transcriptomic analysis, immunofluorescence staining, RT-qPCR, and Seahorse mitochondrial stress assays were performed to elucidate the underlying mechanisms.
Results
Sunitinib treatment significantly impaired macrophage migration and tissue regeneration in a concentration-dependent manner. Transcriptomic analysis revealed that sunitinib markedly suppressed the PPARγ signaling pathway, reparative gene programs, and mitochondrial metabolism. The density of PPARγ+ macrophages at the wound site was significantly reduced following sunitinib exposure. Treatment with rosiglitazone, a PPARγ agonist, effectively rescued the regeneration defects induced by sunitinib, restored macrophage infiltration, and recovered oxidative phosphorylation. Notably, these rescuing effects were abolished upon macrophage depletion.
Discussion
Our results demonstrate that sunitinib impairs tissue regeneration by suppressing PPARγ signaling and oxidative phosphorylation in macrophages. Targeting the PPARγ pathway represents a promising therapeutic strategy to reverse sunitinib-associated deficits in tissue repair.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, China.
- National Clinical Research Center for Oral Diseases, Peking University School and Hospital of Stomatology, Beijing, China.
- National Engineering Laboratory for Digital and Material Technology of Stomatology, Peking University School and Hospital of Stomatology, Beijing, China.
- Beijing Key Laboratory of Digital Stomatology, Peking University School and Hospital of Stomatology, Beijing, China.
- General Dentistry, Peking University School and Hospital of Stomatology, Beijing, China.
- Department of Histology and Embryology, School of Medicine, Nankai University, Tianjin, China.
Zitieren
APA
Zhang, Z., Qiao, Q., Li, J., Li, Q., Yang, Y., Zhou, Y., Huang, H., Chen, D., Wang, Y., & Guo, Y. (2026). Sunitinib induces macrophage dysfunction and impaired tissue regeneration through suppression of PPARγ. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1900449
Vancouver
Zhang Z, Qiao Q, Li J, Li Q, Yang Y, Zhou Y, et al. Sunitinib induces macrophage dysfunction and impaired tissue regeneration through suppression of PPARγ. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1900449
BibTeX
@article{Zhang2026,
author = {Zhang, Zhouchen and Qiao, Qiao and Li, Jiannan and Li, Qingxiang and Yang, Yuanning and Zhou, Ying and Huang, Hongyuan and Chen, Dongyan and Wang, Yifei and Guo, Yuxing},
title = {Sunitinib induces macrophage dysfunction and impaired tissue regeneration through suppression of PPARγ},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.1900449}
}
EUVIMED